Pharmacoeconomic analysis of Capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer by Douillard, J, Twelves, C, McKendrick, J, Bertetto, O, Coxon, F, Diaz-Rubio, E, Dufour, P, Maughan, T, Scheithauer, W, Burris, H

Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts). by Diaz-Rubio, E, Burris, H, Douillard, J, Coxon, F, Maughan, T, Bertetto, O, Schueller, J, Husseini, F, Marschner, N, Scheithauer, W, Grp, X

Development of a large area InGaAs APD receiver based on an impact ionization engineered detector for free-space lasercomm applications by Burris, H. R., Ferraro, M. S., Freeman, W. T., Moore, C. I., Murphy, J. L., Rabinovich, W. S., Smith, W. R., Summers, L. L., Thomas, L. M., Vilcheck, M. J., Clark, W. R., Waters, W. D.

Get full text

Alpelisib plus fulvestrant in PIK3CA-Altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: A phase 1b clinical trial by Juric, D, Janku, F, Rodón, J, Burris, H, Mayer, I, Schuler, M, Seggewiss-Bernhardt, R, Gil-Martin, M, Middleton, M, Baselga, J, Bootle, D, Demanse, D, Blumenstein, L, Schumacher, K, Huang, A, Quadt, C, Rugo, H